PROTACs have already been applied for the degradation of various notable targets, including abelson murine leukemia viral oncogene homolog 1 (ABL)-breakpoint cluster region (BCR) in chronic myeloid leukemia, bromodomain proteins in multiple cancers, and androgen receptor in prostate cancer (details in Table 1)53,71,72. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.